Quebec health officials are considering a regulatory change that would move Benadryl (diphenhydramine) from open shelves to behind pharmacy counters, aiming to reduce misuse and improve public safety. The proposal, reported by Montreal News on July 9, 2026, follows growing concerns about the antihistamine's potential for abuse and adverse effects when taken in large doses.
Why Benadryl Is Under Scrutiny
Benadryl, a common over-the-counter allergy medication, contains diphenhydramine, which can cause sedation and, in high amounts, serious side effects such as hallucinations, seizures, and heart problems. Health authorities in Quebec have noted an increase in incidents related to its misuse, particularly among teenagers attempting to experience a "high." According to a statement from the Quebec Ministry of Health, the move is part of a broader effort to align with best practices in medication safety observed in other jurisdictions.
"We are evaluating the evidence and consulting with pharmacists and healthcare professionals to determine if reclassification is the best course of action," said a ministry spokesperson. The proposal would require a prescription or pharmacist intervention to purchase Benadryl, similar to how certain cold medications containing pseudoephedrine are managed.
Impact on Consumers and Pharmacies
If implemented, the change would affect millions of Quebecers who use Benadryl for allergies, sleep aid, or motion sickness. Pharmacists would need to assess each purchase, potentially limiting access but also providing an opportunity to counsel patients on proper use. The Quebec Order of Pharmacists has expressed support for the measure, citing the need to prevent misuse while ensuring the drug remains accessible for legitimate medical needs.
"This is about striking a balance between availability and safety," said Dr. Marie-Claude Bouchard, a spokesperson for the order. "We see this as a positive step toward responsible medication management." The proposal has drawn mixed reactions from the public, with some praising the safety focus and others concerned about convenience.
Broader Context and Next Steps
Quebec's consideration mirrors similar moves in other countries. For instance, Australia reclassified diphenhydramine as a pharmacy-only medicine in 2020 due to abuse concerns. The Quebec government plans to hold public consultations over the coming months before making a final decision. A timeline for implementation, if approved, has not been set.
The proposal is part of a larger trend in Canada to tighten controls on over-the-counter drugs with potential for harm. Earlier this year, Health Canada launched a review of cough and cold medications containing codeine. Quebec's move could set a precedent for other provinces to follow.
